All Stories

  1. Respiratory viruses: their importance and lessons learned from COVID-19
  2. Outcomes of Critically ill Very old patients with Acute Respiratory Distress Syndrome and Community-Acquired Pneumonia
  3. Impact on in-hospital mortality of Ceftaroline versus standard of care in Community-Acquired Pneumonia: A Propensity Matched Analysis
  4. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia
  5. Pulse oximetry is an essential tool that saves lives: a call for standardisation
  6. PES Pathogens in Elderly Patients with Acquired Pneumonia in the Community
  7. Awareness and Pneumonia knowledge: where to start educating?
  8. Methicillin-susceptible Staphylococcus aureus in Community-Acquired Pneumonia: Risk Factors and Outcomes
  9. Can Artificial Intelligence Improve the Management of Pneumonia
  10. Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning
  11. Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients
  12. Prevalence and risk factors of sepsis in very old patients with CAP
  13. non invasive diagnosis of nosocomial pneumonia
  14. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia
  15. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired pneumonia
  16. lymphopenia predicts mortality in patients with ICU pneumonia
  17. Addendum: Cillóniz, C.; Dominedò, C.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms 2019, 7, 49
  18. Evaluation of the Magicplex™ Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in Adults
  19. Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia
  20. PES Pathogens in Severe Community-Acquired Pneumonia
  21. An international perspective on hospitalized patients with viral community-acquired pneumonia
  22. Early noninvasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia
  23. Community-acquired pneumonia as an emergency condition
  24. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients with Community-Acquired Pneumonia
  25. Reply to Head and Keynan
  26. Drugs that increase the risk of community-acquired pneumonia: a narrative review
  27. Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART
  28. Clinical Approach to Community-acquired Pneumonia
  29. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study
  30. Inflammatory response depends on time since onset of symptoms in pneumonia
  31. MagicplexTM Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults
  32. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia
  33. Burden and risk factors forPseudomonas aeruginosacommunity-acquired pneumonia: a multinational point prevalence study of hospitalised patients
  34. Community-acquired bacterial pneumonia in adult HIV-infected patients
  35. Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease
  36. Community-acquired Pneumonia and Acute Respiratory Distress Syndrome
  37. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging
  38. Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus–Infected Adult Patients: A Matched Case-Control Study
  39. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review
  40. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis
  41. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia
  42. Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients
  43. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients
  44. New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study
  45. Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress
  46. Has Mortality of Community-Acquired Pneumonia Really Reduced?
  47. Predictors of treatment failure and clinical stability in patients with community acquired pneumonia
  48. Adjuvant therapies in critical care: steroids in community-acquired pneumonia
  49. Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia
  50. Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality
  51. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
  52. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study
  53. Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia
  54. Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients
  55. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial
  56. Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia
  57. Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia
  58. Typical Presentation of Legionella pneumophila Community-Acquired Pneumonia
  59. Research in community-acquired pneumonia: the next steps
  60. Seasonality of pathogens causing community-acquired pneumonia
  61. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns
  62. Laboratory diagnosis of pneumonia in the molecular age
  63. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome
  64. Clinical management of community acquired pneumonia in the elderly patient
  65. Response
  66. Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosa
  67. Community-acquired pneumonia related to intracellular pathogens
  68. Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia
  69. What is the clinical relevance of drug-resistant pneumococcus?
  70. Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia
  71. Pneumococcal vaccination
  72. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis
  73. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis
  74. Bacteraemia in outpatients with community-acquired pneumonia
  75. Polymicrobial community-acquired pneumonia: An emerging entity
  76. Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia
  77. Ceftobiprole for the treatment of pneumonia: a European perspective
  78. Streptococcus pneumoniae-associated pneumonia complicated by purulent pericarditis: case series
  79. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients
  80. New antimicrobial approaches to gram positive respiratory infections
  81. Macrolide resistance and outcomes of patients with Streptococcus pneumoniae pneumonia.
  82. Risk Factors Associated with Potentially Antibiotic-Resistant Pathogens in Community-Acquired Pneumonia
  83. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis
  84. Severe community-acquired pneumonia: Severity and management
  85. Noninvasive ventilation for acute respiratory failure due to community-acquired pneumonia: A concise review and update
  86. Clinical Management of Bacterial Pneumonia
  87. Viral infections
  88. Detection of Pneumonia Associated Pathogens Using a Prototype Multiplexed Pneumonia Test in Hospitalized Patients with Severe Pneumonia
  89. Severity and outcomes of community acquired pneumonia in asthmatic patients
  90. Predicting treatment failure in patients with community acquired pneumonia: a case-control study
  91. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
  92. Lung abscess due to Streptococcus pneumoniae: a case series and brief review of the literature
  93. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study
  94. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome
  95. IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia
  96. Pneumococcal disease: Epidemiology and new vaccines
  97. Community-acquired viral pneumonia in human immunodeficiency virus infected patients
  98. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis
  99. Predicting Community-Acquired Pneumonia Etiology: Response
  100. A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia
  101. IgM levels in plasma predict outcome in severe pandemic influenza
  102. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case–control study
  103. Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia
  104. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table 1
  105. Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-acquired Pneumonia
  106. Thrombocytosis Is a Marker of Poor Outcome in Community-Acquired Pneumonia
  107. Epidemiology, Clinical Features, and Prognosis of Elderly Adults with Severe Forms of Influenza A (H1N1)
  108. Systemic corticosteroids for community-acquired pneumonia: Reasons for use and lack of benefit on outcome
  109. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia
  110. Influenza A (H1N1) Pneumonia
  111. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes
  112. Invasive Pneumococcal Disease Today
  113. Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia
  114. Entendimento da mortalidade em pneumonia pneumocócica bacterêmica
  115. Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia
  116. Pulmonary Complications Of Pneumococcal CAP: Incidence, Predictors, And Outcomes
  117. Corticosteroids In Community-Acquired Pneumonia: Therapeutic Reasons And Outcomes
  118. Influence Of Long-Term Use Of Inhaled Corticoids On The Development Of Pleural Effusion In Community Acquired Pneumonia
  119. Thrombocytosis Is A Diagnostic And Prognostic Marker In Community-Acquired Pneumonia
  120. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza
  121. Community-acquired pneumonia in outpatients: aetiology and outcomes
  122. CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients
  124. Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1
  125. First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain
  126. Microbial aetiology of community-acquired pneumonia and its relation to severity
  127. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis
  128. Pandemic and post-pandemic Influenza A (H1N1) infection in critically ill patients
  129. Influenza pneumonia: a comparison between seasonal influenza virus and the H1N1 pandemic
  130. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia
  131. Severe Mixed Community Acquired Pneumoniae
  132. Community-acquired Pneumonia In Outpatients: Microbial Etiology
  135. Healthcare-associated Pneumonia (HCAP): Clinical Features And Biomarkers
  136. Nursing home-acquired pneumonia: a 10 year single-centre experience
  137. Impact of Smoking Habit on the Etiology of Community-Acquired Pneumonia (CAP).
  138. Community-Acquired Pneumonia: Etiology and Severity Scores.
  139. Complicated Pneumococcal Pneumonia in Adults.